Clinical Trial Update: Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC [Phase 2]

View source ↗

Summary

Phase 2 trial exploring the combination of sintilimab with stereotactic body radiotherapy in advanced metastatic hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Stage IV HCC, Immunotherapy | Phase 2 | Status: UNKNOWN